Abstract:Objective: The dynamic adaptive immune responses elicited by the inactivated virus vaccine CoronaVac remain elusive. Methods: In a prospective cohort of 100 healthcare professionals naive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received two doses of CoronaVac, we analysed SARS-CoV-2-specific humoral and cellular responses at four different timepoints, including before vaccination (T1), 2 weeks after the first dose (T2), 2 weeks after the booster dose (T3), and 8-10 weeks after the booster dose (T4). SARS-CoV-2-specific antibodies, serum neutralizing activities, peripheral B cells, CD4(+) and CD8(+) T cells and their memory subsets were simultaneously measured in this cohort. Results: SARS-CoV-2 spike-specific IgG responses reached a peak (geometric mean titre (GMT) 54827, 30969-97065) after two doses and rapidly declined (GMT 502, 212-1190) at T4, whereas suboptimal IgA responses were detected (GMT 5, 2-9). Spike-specific circulating B cells (0.60%, 0.46-0.73% of total B cells) and memory B cells (1.18%, 0.92-1.44% of total memory B cells) were effectively induced at T3 and sustained over time (0.33%, 0.23-0.43%; 0.87%, 0.05-1.67%, respectively). SARS-CoV-2-specific circulating CD4(+) T cells (0.57%, 0.47-0.66%) and CD8(+) T cells (1.29%, 1.04-1.54%) were detected at T3. At T4, 0.78% (0.43-1.20%) of memory CD4+ T cells and 0.68% (0.29-1.30%) of memory CD8(+) T cells were identified as SARS-CoV-2-specific, while 0.62% (0.51-0.75%) of CD4(+) T cells and 0.47% (0.38-0.58%) of CD8(+) T cells were SARS-CoV-2-specific terminally differentiated effector memory cells. Furthermore, age and interval between doses affected the magnitude of CoronaVac-induced immune responses. SARS-CoV-2 memory CD4(+) T cells were strongly associated with both receptor binding domain (RBD)-specific memory B cells (r 0.87, p <0.0001) and SARS-CoV-2-specific memory CD8(+) T cells (r 0.48, p <0.0001). Conclusions: CoronaVac induced robust circulating and memory B cell and T cell responses. Our study offers new insight into the underlying immunobiology of inactivated virus vaccines in humans and may have implications for vaccine strategies in the future. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Pre‐existing Immunity to SARS‐CoV‐2 Associates with Strong T Cell Responses Induced by Inactivated COVID‐19 Vaccines

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization

Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

Non-spike and Spike-Specific Memory T Cell Responses after the Third Dose of Inactivated COVID-19 Vaccine

Clinical and laboratory features in health care volunteers with inactivated SARS-CoV-2 vaccination

Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.

Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

Seasonal Coronaviruses and SARS-CoV-2: Effects of Preexisting Immunity During the COVID-19 Pandemic

SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine

Neutralizing Antibodies and Cellular Immune Response after Two Doses of Inactivated SARS-CoV-2 Vaccine in China.

Single-cell transcriptomic atlas of individuals receiving inactivated COVID-19 vaccines reveals distinct immunological responses between vaccine and natural SARS-CoV-2 infection

Comparative Single-Cell RNA Sequencing Analysis of Immune Response to Inactivated Vaccine and Natural SARS-CoV-2 Infection

Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination

B-086 Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure

Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence

Robust Induction of B Cell and T Cell Responses by a Third Dose of Inactivated SARS-CoV-2 Vaccine

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination